Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (GB:0HFR)
:0HFR
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.14Last Year’s EPS
-0.14Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -10.50%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in Alzheimer's and schizophrenia treatment development, supported by a strong financial position and strategic board appointments. However, the company continues to face challenges with net losses and regulatory uncertainties.Company Guidance
During the Anavex Life Sciences Fiscal 2025 Second Quarter Conference Call, key guidance and updates were provided regarding the company's progress and financial status. The company highlighted its ongoing focus on advancing its portfolio of precision compounds, particularly targeting Alzheimer's disease and schizophrenia. For Alzheimer's, the open-label extension data of blarcamesine showed continued clinically meaningful benefits over three years, demonstrating significant improvement in clinical decline measured by ADAS-Cog13 and ADCS-ADL. In schizophrenia, the Phase 2 clinical study of ANAVEX3-71 has successfully completed enrollment with 71 participants, and top-line data is expected in the second half of 2025. Financially, Anavex reported a cash position of $115.8 million as of March 31, 2025, with no debt, and a net loss of $11.2 million or $0.13 per share for the quarter. The company anticipates a runway of approximately four years at its current cash utilization rate.Significant Advancement in Alzheimer's Treatment
Open-label extension data of blarcamesine for Alzheimer's disease confirmed continued clinically meaningful benefits for early Alzheimer's disease patients. Over three years of continuous treatment, significant amelioration on clinical decline was observed, with benefits accruing up to four years.
Progress in Schizophrenia Clinical Trials
Successful completion of enrollment in the Phase 2 clinical study of ANAVEX3-71 for schizophrenia. Part A completed with encouraging preliminary safety and EEG biomarker results. Part B will provide more comprehensive data, with top-line data expected in the second half of this year.
Strong Financial Position
Cash position as of March 31st was $115.8 million with no debt, providing a runway of approximately four years.
Expansion of Scientific Advisory Board
Appointment of Professor Dr. Audrey Gabelle, a specialist in predictive, personalized medicine and digital healthcare in Alzheimer's disease, to the Anavex Scientific Advisory Board.
GB:0HFR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
GB:0HFR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $8.57 | $8.31 | -2.98% |
Feb 12, 2025 | $8.51 | $8.39 | -1.47% |
Dec 23, 2024 | $8.63 | $11.38 | +31.90% |
Aug 06, 2024 | $6.57 | $6.94 | +5.71% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Anavex Life Sciences (GB:0HFR) report earnings?
Anavex Life Sciences (GB:0HFR) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Anavex Life Sciences (GB:0HFR) earnings time?
Anavex Life Sciences (GB:0HFR) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Anavex Life Sciences stock?
The P/E ratio of Anavex Life Sciences is N/A.
What is GB:0HFR EPS forecast?
GB:0HFR EPS forecast for the fiscal quarter 2025 (Q3) is -0.14.
